Taysha Gene Therapies stock hit an all-time high of $5.49, before pulling back 8% for the week.
Shares surged nearly 100% over the past year, fueled by optimism around gene therapy solutions.
According to Bond.az analysis, the stock is currently trading above Fair Value and is on the Most Overvalued list.
In Q1 2026, the company reported a net loss of $0.12 per share, missing estimates of $0.10 loss. Revenue was zero.
